) induces fusion of vesicles that contain the water channel aquaporin-2 (AQP2) with the plasma membrane of renal collecting duct principal cells. This "AQP2 shuttle" increases the osmotic water permeability (Pf) of the cells, facilitating water reabsorption from the collecting duct (1). The AQP2 shuttle is initiated upon binding of AVP to vasopressin-2 receptors (V2R) and triggered by the consequent cAMP elevation and protein kinase A (PKA) activation. It is the PKA phosphorylation of AQP2 that elicits redistribution of AQP2-bearing vesicles. Pivotal to this redistribution is the compartmentalization of PKA by A kinase anchoring proteins (AKAP) (2). Phosphodiesterases (PDE), which are the sole means of degrading cAMP, are poised to regulate PKA signaling (3-6). The PDE4 family has attracted great interest because of its link to stroke (7), schizophrenia (8), and the therapeutic potential of selective inhibitors for treating inflammatory diseases (9-12). The four subfamilies (PDE4A through D) are encoded by separate genes, generating approximately 20 isoforms (9,11) that can interact with scaffolding proteins, including AKAP and ␤-arrestin (12-16), positioning them for a role in compartmentalized cAMP/PKA signaling.
Pf Measurements
Water permeability was measured by imposing an osmotic gradient across an IMCD cell monolayer and measuring changes in solute concentration at the basolateral plasma membrane with Mg 2ϩ -sensitive microelectrodes (19) (glass capillaries, filled at their tips with Mg 2ϩ ionophore II; Fluka, Buchs, Switzerland). The Mg 2ϩ concentration distribution was fitted to a uniexponential function to determine the velocity of water flow (20) . Pf were calculated with respect to the increased bulk viscosity (2.9 cP in 300 mM polyethylene glycol) and the near-membrane osmolyte dilution (20, 21) .
Immunofluorescence and Immunogold Electron Microscopy
Analyses of IMCD cells and cryosections that were obtained from Sprague-Dawley rat renal inner medullae were performed as described previously (2, 17, 22, 23) . AQP2 was detected using rabbit or goat antisera (2, 17, 22, 23) . Sheep polyclonal antisera were used to detect individual PDE4 subfamilies (24 -28) . PDE4D also was stained with monoclonal mouse antibodies (gift from Dr. Sharron Wolda, ICOS, Bothell, WA) (24, 27, 28) . The PKA-phosphorylated serine within upstream conserved region 1 (UCR1) of PDE4 was detected with rabbit antiserum PS54-UCR1-A1 (29) . Secondary Cy3-, Cy5-, and FITC-conjugated antibodies and antibodies that were coupled with 18 or 10 nm of gold grains were purchased from Dianova (Hamburg, Germany). Immunofluorescence signals were visualized with a laser-scanning microscope (LSM 510; Zeiss, Jena, Germany).
To quantify AVP, IBMX, and rolipram effects on localizations of AQP2, we determined PDE4D and p-PDE4D, the intracellular/plasma membrane fluorescence signal intensities (2, 17, 22, 23) . The ratio between both signals (intracellular/plasma membrane) was calculated. From these data, the kinetics of the AVP-induced translocation of AQP2 and p-PDE4D were derived according to the equation R(t) ϭ R min ϩ Figure 1 . Arginine vasopressin (AVP) induces focal activation of protein kinase A (PKA) in inner medullary collecting duct (IMCD) cells. (A) IMCD cells were treated with the indicated substances (H89, 30 M; AVP, 100 nM; forskolin, 100 M; 15 min) and lysed, and PKA activities were determined. Measurements were carried out in the presence of protein kinase C and calmodulin-dependent kinase inhibitors (n ϭ 3 independent experiments, means Ϯ SEM). (B) IMCD cells were transfected with a plasmid that encodes the PKA activity reporter A-kinase activity reporter (AKAR1) (top). Expression of AKAR1 was confirmed by the fluorescence that was emitted by yellow fluorescence protein (YFP) after excitation at 488 nm. Fluorescence resonance energy transfer (FRET) measurements were carried out with living cells before treatment (0 min) with AVP (100 nM), H89 (30 M) and AVP, or forskolin (100 M) and thereafter at the indicated time points. FRET from cyan fluorescent protein (CFP) to YFP was determined by excitation of CFP and measurement of the fluorescence that was emitted from YFP (535/26 nm). FRET is depicted in false colors. FRET signals are increasing from blue to red, with red being the maximal FRET. The color scaling describes the first 128 stages of an 8-bit grayscale (0 to 255). As a control, IMCD cells were co-transfected with plasmids that encode CFP or YFP (middle). The changes of relative FRET during treatments with the indicated agents are shown in the bottom.
(R max Ϫ R min ) ϫ exp(Ϫt/T), where R is the ratio, t is time, and T is half-life time.
Immunoisolation of Intracellular Vesicles
A rabbit polyclonal antiserum (A18␦3; Biogenes, Berlin, Germany) that recognizes both AKAP18␦ and AKAP18␥ was raised against a peptide (amino acid residues 55 to 76 of AKAP18␦) (17) . Affinitypurified antibodies from this and an AQP2 rabbit antiserum (see previous section) (17) were conjugated with Eupergit C1Z methacrylate microbeads (Roehm Pharma, Darmstadt, Germany) (17) . Nonspecific binding was blocked with glycine. Control beads were coated with glycine alone. For immunoisolation of intracellular vesicles, six dishes (60 mm) of IMCD cells (6 ϫ 10 6 cells/dish) were used (17) .
Immunoprecipitation
AKAP18 was immunoprecipitated with antibody A18␦5, which precipitates AKAP18␦. AKAP18␦-YFP constructs were immunoprecipitated using anti-GFP antibodies (30) .
Western Blotting and RII Overlay
This was performed as before (17, 23) . AQP2 and PDE4D isoforms were detected using the previously indicated antisera. PKA regulatory RII␤ subunits (BD Biosciences, Heidelberg, Germany), AQP4 (Biotrend Chemikalien, Cologne, Germany), calnexin (Dianova), calreticulin (Dianova), and ␣-tubulin (Oncogene Research Product, Calbiochem, Cambridge, MA) were detected with commercial mAB. Secondary horse- Figure 2 . Inhibition of phosphodiesterase 4 (PDE4) enhances the AVP-induced accumulation of cAMP (A), the aquaporin-2 (AQP2) shuttle (A), and the osmotic water permeability (Pf; C) in IMCD cells. (A) IMCD cells were left untreated (control) or incubated with AVP (100 nM), forskolin (100 M), the nonselective PDE inhibitor IBMX (250 M), rolipram (100 M), or the indicated combinations. The cellular content of cAMP was determined by RIA at the indicated times (n ϭ 4 independent experiments, means Ϯ SEM). Data points were fitted by nonlinear regression curve fitting (polynomial equation, third order) using GraphPad Prism software version 3.02 (GraphPad Prism Software, San Diego, CA). AVP, forskolin, or combinations of the two agonists with rolipram or IBMX induced significantly higher elevations of cAMP levels compared with controls (P Ͻ 0.05, t test). (B) Detection of AQP2 in IMCD cells that were left untreated or incubated with AVP (100 nM), rolipram (100 M), or IBMX (100 M) for 15 min each. Where indicated, cells were preincubated with rolipram or IBMX before AVP stimulation. Bars ϭ 20 m. The intracellular and plasma membrane fluorescence signal intensities were determined, related to nuclear signal intensities, and ratios of intracellular/plasma membrane signal intensities were calculated (n Ն 16 cells for each condition tested; means Ϯ SEM; three independent experiments). Ratios Ͼ1 indicate a mainly intracellular and ratios Ͻ1 a predominant localization of AQP2 at the plasma membrane. P Ͻ 0.001 versus *control and 
PDE4 and PKA Measurements and RIA
Activities were measured using 20 g of protein/25 l AQP2-bearing vesicle fractions or with 25 l of control fractions. PDE4 activity is that specifically inhibited by the PDE4-selective inhibitor rolipram (10 M) (9, 11, 31) . PKA activity was measured using a commercial assay (Upstate/Biomol, Hamburg, Germany). The cellular cAMP content was determined by RIA as performed before (32) .
Fluorescence Resonance Energy Transfer
A-kinase activity reporter (AKAR1) is a fusion of cyan fluorescent protein (CFP) and YFP separated by a sequence that encompasses a PKA consensus phosphorylation site. Its phosphorylation triggers a conformational change yielding fluorescence resonance energy transfer (FRET) (33) . FRET measurements were performed as described previously (17, 33) . Background fluorescence was subtracted from the data. A ratio of 535 nm/480 nm Ͼ0.6 was considered a positive FRET signal. CFP and YFP that were expressed as soluble proteins provided a negative control (17) . FRET was verified by measurement of donor recovery after acceptor bleaching (17) and quantitatively evaluated from selected areas of cells.
SPOT Synthesis and Overlay Experiments
Peptides were SPOT-synthesized on cellulose membranes and overlain with recombinant AKAP18␦-GST, PDE4D3-GST, or GST (10 g/ml) (16) . Interactions were detected with rabbit anti-GST and secondary horseradish peroxidase antibody by a procedure identical to Western blotting.
Results

AVP Induces Focal Activation of PKA
Both forskolin, a direct activator of adenylyl cyclase, and AVP induce the AQP2 shuttle in IMCD cells to a similar extent (23) . However, forskolin raises PKA activity ( Figure 1A ) and cAMP ( Figure 2A ) levels two-fold higher than AVP. Thus, the level of activation of the AQP2 shuttle is not determined simply by the global level of cAMP and PKA activity. For elucidation of whether forskolin and AVP induce PKA activation at different locations, the FRET-based PKA activity reporter AKAR1 was expressed in IMCD cells. Its phosphorylation by PKA yields an increase in FRET, allowing visualization of PKA activation (33) . In IMCD cells that express AKAR1, AVP increases FRET perinuclearly ( Figure 1B) , where AQP2 and PKA predominantly are found ( Figures 2B and 3 ) (34) . In contrast, forskolin increases FRET throughout the cells ( Figure 1B ). Thus, focal PKA activation is sufficient to trigger the AQP2 shuttle. The FRET signals are depicted as the ratio of 535 nm/480 nm in false colors (ratio 1.2 to 1.5; Figure 1B ). Coexpression of soluble CFP and YFP did not yield FRET (ratio Ͻ0.6; Figure 1B ). Thus, CFP and YFP need to be in close proximity (Ͻ10 nm) and physically associated for FRET to occur. AVP-induced increases in PKA activity ( Figure 1A ) and FRET ( Figure 1B) were PKA dependent as they were prevented by H89.
Inhibition of PDE4 Increases Pf and the AQP2 Shuttle
AVP-induced focal activation of PKA suggests that PKA is tethered to cellular compartments and that compartmentalization of cAMP signaling by PDE plays a role in the AQP2 shuttle. For evaluation of whether PDE4 enzymes are involved in this process, their activity was ablated in IMCD cells using the selective inhibitor rolipram (9, 11) . Neither rolipram nor the nonselective PDE inhibitor IBMX had any marked effect on basal cAMP levels. Both, however, enhanced cAMP accumulation in response to AVP or forskolin. Together, forskolin and rolipram caused cAMP accumulation to five-fold higher levels than the combination of AVP and rolipram ( Figure 2A ).
In resting IMCD cells, AQP2 is localized mainly on intracellular vesicles ( Figures 2B and 3 ). AVP causes its redistribution, predominantly into the basolateral plasma membrane (2, 17, 19, 22, 23) (➜,  18 nm of gold particles) and PDE4D (3, 10 nm of gold particles) were detected by using the same primary antibodies as in C (Bar ϭ 500 nm). The lower image was assembled from two separately recorded images using analySIS software. The magnified views show representative vesicles and plasma membrane regions. (Top right) Intracellular vesicles (n ϭ 246) in images from control cells that were obtained from three independent experiments were analyzed for the presence of AQP2 and/or PDE4D. Shown is the percentage of vesicles that contained AQP2, PDE4D, or both (means Ϯ SEM). (Bottom right) The numbers of gold particles/m plasma membrane in control and AVP-treated IMCD cells were determined from n ϭ 63 and n ϭ 101 images from three independent experiments, respectively (means Ϯ SEM). (E) Cryosections from rat renal inner medulla of control and desmopressin-treated rats were incubated with sheep anti-PDE4D and secondary Cy5-conjugated antibodies and subsequently with rabbit anti-AQP2 and secondary Cy3-conjugated antibodies. Fluorescence signals were visualized by epifluorescence microscopy. Magnification, ϫ300.
The enhancing effect of rolipram on the AQP2 shuttle underestimates the effect of rolipram on the Pf. Whereas in resting conditions rolipram does not alter Pf, it enhances the Pf value approximately 30% in forskolin-stimulated cells ( Figure 2C ). For unknown reasons, IMCD cells do not respond to AVP with an increase in Pf in this experimental setting; therefore, experiments were performed with forskolin. These data indicate a role for PDE4 in the control of the AQP2 shuttle and suggest that local instead of global increases of cAMP trigger the shuttle.
PDE4D and AQP2 Co-localize and, in Response to AVP, Co-Translocate to the Plasma Membrane
We used specific antisera to determine which PDE4 enzymes are involved in the AQP2 shuttle. Immunoblotting of postnuclear supernatants identified proteins that co-migrated with recombinant PDE4B2 and PDE4D1, D3, and D5. Bands whose apparent molecular weights do not correspond in size to known PDE4 isoforms likely represent degradation products ( Figure 3A ).
PDE4 that is tethered to AQP2-bearing vesicles is poised to regulate vesicle-associated PKA by local hydrolysis of cAMP (17) . For identification of these species, vesicles were immunoisolated from rat renal inner medullae using beads coated with anti-AQP2 antibody (AQP2AB beads; Figures 3A and 5A) . Compared with the fraction that was obtained with control beads (without antibody), fractions that were isolated with AQP2AB beads clearly are enriched in glycosylated (g) and nonglycosylated (ng) AQP2 and regulatory RII␤ subunits of PKA ( Figure 5A ). It is intriguing that a 98-kD PDE4D immunoreactive species was enriched in this fraction (Figures 3A and 5A) and was not recognized by preimmune serum (data not shown). PDE4D3, PDE4D8, and PDE4D9 isoforms migrate similarly at approximately 98 kD on SDS-PAGE (36) . Reverse transcriptase-PCR experiments with isoform-specific primers iden- 100 nM, 15 min) . AQP2, PDE4D, and p-PDE4 staining was performed using goat-anti AQP2/Cy3-conjugated secondary antibodies, mouse PDE4D/Cy5-conjugated secondary antibodies, and rabbit anti p-PDE4/FITC-conjugated secondary antibodies. The overlays of fluorescence signals are shown on the right. As a control, IMCD cells were preincubated with the PKA inhibitor H89 before AVP treatment (middle). Images for quantitative analysis were taken from control and AVP-treated cell after the indicated times (bottom left). Details of the quantification are described in the legend to Figure 2B . From these data, the kinetics of the AVP-induced translocation of AQP2 and p-PDE4 were derived according to the equation R(t) ϭ Rmin ϩ (R max Ϫ R min ) ϫ exp(Ϫt/T), where R is ratio (see above), t is time. (A) Intracellular vesicles were obtained from PNS that were prepared from rat renal inner medullae with AQP2 antibody beads (AQP2AB beads). Control fractions were obtained with beads without antibody. Glycosylated (g) and nonglycosylated (ng) AQP2; regulatory RII␤ subunits of PKA; PDE4D (isoforms PDE4D3 and/or PDE4D9, PDE4D3/9); and, as controls, markers for the plasma membrane (AQP4-g), the cytoskeleton (␣-tubulin), the endoplasmic reticulum (ER; calreticulin), and mitochondria (cytochrome c subunit IV [COXIV]) were detected by Western blotting. IgG H , heavy chain of anti-AQP2 antibody coupled to AQP2 beads. Densitometric analyses of Western blots (bottom) are shown as the ratios of densitometric signals AQP2AB/control beads (n ϭ 3 independent experiments, means Ϯ SEM). The scheme depicts proteins that were associated with AQP2-bearing vesicles: AKAP18␦, PKA (RII and C subunits), and PDE4D3/9. (B) Total cAMP PDE and PDE4 activities that were associated with AQP2-bearing vesicles (AQP2AB beads) or the control fractions were assayed with 1 M cAMP as substrate. Abundance of PDE4 activity is defined as the fraction that is inhibited by 10 M rolipram (means Ϯ SD; n ϭ 3 independent experiments). (C) PKA activities that were associated with AQP2-bearing vesicles (AQP2AB beads) and a control fraction (control beads) were determined. Measurements were carried out in the presence of PKC and calmodulin-dependent (CaM) kinase inhibitors and, where indicated, in the presence of the PKA anchoring disruptor peptide Ht31 (100 M), the control peptide Ht31-P (100 M), or the PKA inhibitor peptide PKI (100 M; n ϭ 3 independent experiments, means Ϯ SEM). The scheme tified transcripts for PDE4D3 and PDE4D9 (data not shown), indicating that PDE4D3 and/or PDE4D9 are associated with AQP2-bearing vesicles. Other PDE4 isoforms were not detectable (PDE4B) or not enriched (PDE4A and C) in the AQP2-bearing vesicle fractions ( Figure 3A) . Markers for the plasma membrane (g-AQP4), the cytoskeleton (␣-tubulin), the endoplasmic reticulum (calreticulin), and mitochondria (cytochrome c subunit IV) are hardly detectable in the vesicle fractions ( Figure 5A ), indicating that contamination from other cellular compartments is negligible.
In immunofluorescence microscopic analyses, PDE4B is not detectable in IMCD cells (data not shown). PDE4A and PDE4C are detected throughout resting cells, including nuclei and plasma membranes ( Figure 3B ). PDE4D is localized predominantly intracellularly, including the nuclei ( Figure 3C ). Although AVP does not change the cellular distribution of PDE4A and PDE4C (Figure 3B) , it induces accumulation of PDE4D in the nucleus and with AQP2 at the plasma membrane ( Figure  3C ). Preincubation of PDE4D antibody with recombinant PDE4D3 strongly reduces fluorescence signals, underlining the specificity of the labeling. Co-localization and co-translocation of AQP2 and PDE4D was confirmed by immunoelectron microscopy ( Figure 3D ). Similar observations were made with kidney sections that were derived from control rats and rats that were treated with the V2R agonist desmopressin ( Figure  3E ). Here, AQP2 and PDE4D were located intracellularly in resting principal cells and mainly at the plasma membrane in desmopressin-stimulated cells. A quantitative evaluation of the intracellular or plasma membrane-derived epifluorescence signals in tissue sections is not possible because fluorescence signals from several layers cannot be separated. These data indicate a role of PDE4D3/9 in the AQP2 shuttle.
PDE4D at the Plasma Membrane Modulates the Pf of IMCD Cells after Elevation of cAMP
Ser54 phosphorylation of PDE4D3 by PKA causes an increase in its activity (37, 38) . Ser54 is localized in UCR1, which is conserved in all long PDE4 isoforms (29) , and its phosphorylation can be detected using a P-UCR1 antibody (29) . Immunofluorescence microscopy revealed that PKA-phosphorylated PDE4 (p-PDE4) is present intracellularly, including the nuclei, and weakly at the plasma membrane of resting IMCD cells ( Figure 4A ). AVP reduces the intracellular content of p-PDE4 and results in the accumulation of p-PDE4 in the nucleus and at the plasma membrane. This is confirmed by quantitative analyses of the immunofluorescence images ( Figure 4A ). The PKA inhibitor H89 reduces the overall signal of p-PDE4 immunoreactivity in resting cells and prevents AVP-induced redistribution. PDE4D3/9 is/are located on AQP2-bearing vesicles and, together with AQP2, translocate/s to the plasma membrane upon AVP challenge. PDE4D3/9 and p-PDE4 have a very similar cellular distribution, overlapping with the distribution of AQP2 in both resting and AVP-treated cells ( Figure 4A ). AVP-induced redistribution of AQP2 and p-PDE4 follows the same kinetics, suggesting that accumulation of p-PDE4 at the plasma membrane is due predominantly to the delivery of PKA-phosphorylated PDE4D3/9 from AQP2-bearing vesicles (Figures 3, 5,  and 6 ).
The AVP-induced increase in p-PDE4 and hence PDE4D activity in the vicinity of the plasma membrane may serve to lower PKA activity, thereby decreasing the Pf of IMCD cells similarly to effects that are observed when PKA is inhibited with H89 (39) . To assess this, we measured changes in Pf of IMCD cell monolayers ( Figure 4B) . Rolipram enhances the forskolin-induced increase in Pf ( Figures 2C and 4B) . Addition of H89, subsequent to rolipram, reduces the Pf to a level that is comparable to that observed after forskolin treatment ( Figure  4B ). If, however, H89 is added to the forskolin-treated cells before rolipram, then the Pf is reduced to basal levels. These data suggest that increased p-PDE4 at the plasma membrane is involved in reducing the cAMP-dependent increase in Pf.
PDE4D Modulates PKA Activity Anchored to AQP2-Bearing Vesicles by AKAP
Co-localization of PKA and PDE4D on AQP2-bearing vesicles (17) (Figures 3A and 5C ) suggests that PDE4D modulates vesicular PKA activity by degrading cAMP. To address this, we determined the dependence of PKA on PDE4D activity on immunoisolated AQP2-bearing vesicles. Of total vesicular PDE activity, Ͼ75% is contributed by PDE4 ( Figure 5B ), specifically PDE4D3/9 ( Figures 3A and 5A) . Enrichment of RII␤ subunits in the vesicular fraction indicated the presence of PKA ( Figure 5D ) and was confirmed by activity measurements ( Figure 5, C and  D) . The PKA inhibitor peptide (PKD) reduced vesicular PKA activity to control levels, and treatment with Ht31, a peptide that disrupts PKA binding to AKAP (17) , decreases vesicular PKA activity by 50% ( Figure 5C ). Therefore, PKA is tethered to AQP2-bearing vesicles by AKAP ( Figure 5A ).
If PDE4D controls vesicular PKA activity, then its inhibition would be expected to increase the amount of cAMP in the vicinity of the vesicles, thereby increasing vesicular PKA activity. PKA activation is associated with dissociation of catalytic from regulatory subunits. Therefore, AQP2-bearing vesicles that are immu- Lysates from rat renal inner medulla were prepared and subjected to immunoprecipitation (IP) with AKAP18 antibody or preimmune serum. The precipitated proteins were probed for the presence of PDE4D by immunoblotting (Western blotting [WB] ) and for binding to 32 P-labeled RII subunits of PKA in RII overlay analyses. The antibody precipitates predominantly AKAP18␦. However, the precipitates contain small amounts of AKAP18␥ and hardly detectable amounts of AKAP18␣ and ␤. (B) Intracellular vesicles were obtained from PNS that were prepared from rat renal inner medullae with AKAP18 antibody beads (AKAP18AB beads).
noisolated from rolipram-treated cells would be expected to contain less PKA activity than vesicles that are obtained from control cells (scheme in Figure 5D ). Indeed, PKA activity on AQP2-bearing vesicles from rolipram-treated IMCD cells is decreased by approximately 35% (Figure 5D) . One of the AKAP that anchors PKA to the vesicles is AKAP18␦ (17) . Elevation of cAMP causes the dissociation of regulatory RII subunits from AKAP18␦ (17) . Consistently, the amount of PKA regulatory RII␤ subunits on AQP2-bearing vesicles is decreased by approximately 40% in rolipram-treated IMCD cells, underlining the regulatory function of PDE4D for vesicular AKAP-anchored PKA ( Figure 5D ).
AKAP18␦ Is an Anchor for PDE4D
What is the underlying mechanism of PDE4D anchoring to AQP2-bearing vesicles? PDE4D3 can interact with mAKAP and AKAP450 (13, 14, 40) , but mAKAP is not expressed in IMCD cells, whereas AKAP450 is not detectable on AQP2-bearing vesicles (data not shown). Given the predisposition of PDE4D3 to bind to AKAP, we investigated whether PDE4D3 forms complexes with AKAP18. Indeed, AKAP18 antibodies that predominantly precipitate AKAP18␦ ( Figure 6A , RII overlay) co-immunoprecipitated PDE4D3/9 ( Figure 6A , Western blot). Among the AKAP18 isoforms (␣, ␤, ␥, and ␦), AKAP18␦ is the only one that is detectable on AQP2-bearing vesicles (17) . To test whether these vesicles also contain PDE4D, we immunoisolated intracellular vesicles from rat renal inner medullae using beads (AKAP18AB beads) that were coated with anti-AKAP18␦ antibody ( Figure 6B ). The identification of AKAP18␦ on vesicles that were immunoisolated with AQP2AB beads is not possible because AKAP18␦ migrates similarly to the antibody heavy chains of the AQP2 antibody coupled to AQP2AB beads. The use of AKAP18AB beads allowed us to identify an enrichment of AKAP18␦ (17), ng-and g-AQP2, PDE4D, and regulatory RII␤ subunits of PKA in the same vesicular fraction ( Figure 6B ). The fractions contained little evidence of markers for the plasma membrane (ng-AQP4), the cytoskeleton (␣-tubulin), the endoplasmic reticulum (calnexin), and mitochondria (cytochrome c subunit IV). These data indicate that AKAP18␦ and PDE4D3/9 form complexes inside cells and that AKAP18␦ is likely to be involved in the tethering of PDE4D3/9 to AQP2-bearing vesicles.
Overlays of overlapping peptides that represent the entire sequences of PDE4D3 with AKAP18␦-GST revealed two regions of PDE4D3 (residues 341 to 365 and 586 to 610; Figure 6C ) that directly bind AKAP18␦-GST. Substitutions of residues D353 and E355 with arginine (R) or alanine (A) or of residues F598 and F600 with alanines either disrupt or reduce interaction ( Figure 6D) , showing that residues 353 to 355 (DLE) and 598 to 600 (FQF) represent important interaction sites with AKAP18␦ ( Figure 6D ). The reverse experiment (i.e., overlays of peptides that represent the full length of AKAP18␦ with PDE4D3-GST) identified four binding sites on the AKAP ( Figure 6E ). Co-immunoprecipitation experiments with PDE4D3 and AKAP18␦ versions that lacked PDE4D3 binding sites 1 through 3 revealed that only site 4 is essential for the interaction ( Figure 6F ). Full-length AKAP18␦ co-immunoprecipitated PDE4D less efficiently than the deletion mutants AKAP18␦-N67, AKAP18␦-N124, and AKAP18␦-N201, suggesting that the N terminus negatively regulates the interac- Figure 6 . Continued. Control fractions were obtained with beads without antibody. AQP2-g and -ng; regulatory RII␤ subunits of PKA; PDE4D (isoforms PDE4D3 and/or PDE4D9, PDE4D3/9); and markers for the plasma membrane (AQP4-ng), the cytoskeleton (␣-tubulin), the ER (calnexin), and mitochondria (COXIV) were detected by Western blotting. (Bottom) Densitometric analyses of Western blots. Shown are the ratios of densitometric signals AKAP18AB/control beads (n ϭ 3 independent experiments, means Ϯ SEM). (C) Overlapping peptides (25 mers), representing the entire sequence of PDE4D3, were "spotsynthesized" on cellulose membranes. The membranes were overlain with recombinant AKAP18␦-GST or, as a control, with GST alone. Amino acids are shown in the one-letter code. (D) Peptides representing the AKAP18␦ binding domains in PDE4D3 (amino acid residues 331 to 355 and 581 to 605) and versions thereof with the indicated amino acid substitutions (bold, underlined) were spot-synthesized and overlain with AKAP18␦-GST. (E) Overlapping peptides (25 mers), representing the entire sequence of AKAP18␦, were spot-synthesized on cellulose membranes and overlain with recombinant PDE4D3-GST or, as a control, with GST alone. Amino acids are shown in the one-letter code. Numbers 1 through 4 indicate the four domains that interact with PDE4D3. (F) HEK293 cells that coexpress PDE4D3-VSV, the indicated AKAP18␦-YFP fusions, or YFP alone were subjected to IP using anti-GFP antibodies. Numbers indicate amino acid residues of AKAP18␦ (full-length AKAP18␦ contains 353 amino acid residues). The precipitates were analyzed by WB using anti-GFP and anti-PDE4D antibodies. The expression of PDE4D-VSV (detection with PDE4D antibodies) was confirmed by WB using lysates. tion with PDE4D. GST alone does not bind any of the immobilized peptides.
Discussion
We show that PDE4D3/9 are the only PDE4 enzymes that are detectable on AQP2 vesicles that translocate in response to AVP to the plasma membrane. This makes them prime candidates to regulate local cAMP levels and thereby PKA activity in the vicinity of AQP2 in both resting and AVP-stimulated principal cells (Figures 3 and 5) . Other PDE4 isoforms likely play other roles, not being detected on AQP2-bearing vesicles or not being redistributed by AVP challenge. The concept of a local control of cAMP and PKA activity is supported by the finding that PDE4 controls PKA activity that is associated with AQP2-bearing vesicles ( Figure 5D ) and that PDE4 inhibition by rolipram enhances the AVP-induced AQP2 shuttle to a similar extent as the nonselective PDE inhibitor IBMX. However, IBMX potentiates the AVP-induced rise in cAMP to a far greater extent than rolipram does (Figure 2 ). Therefore, a uniform high rise of cAMP has a similar effect on the AQP2 shuttle as a local lower increase in the vicinity of PDE4D3/9 at AQP2-bearing vesicles. Furthermore, AVP induces focal activation of PKA in the perinuclear region, where AQP2 and PKA predominantly are located ( Figures 1B, 2, and 3) (34) . PDE4D3/9 and PKA both reside on AQP2-bearing vesicles, which also contain AKAP ( Figure 6A ) (17, 41) that tether PKA to the vesicles ( Figure 5C ) (41) and underpin activation of the AQP2 shuttle (2). Collectively, our data provide strong evidence for the presence of a compartmentalized cAMP-dependent signaling system on AQP2-bearing vesicles that regulates the AQP2 shuttle and thereby the Pf in renal principal cells (Figure 7) . PDE4 inactivation by rolipram in the absence of AVP does not trigger any significant rise in cAMP or the AQP2 translocation to the plasma membrane (Figure 2 ). This indicates that the basal levels of cAMP that access PKA that is associated with AQP2-bearing vesicles are too low for any localized increase in cAMP that is caused by inhibition of PDE4 to trigger a response. Such low cAMP at this locality presumably maintains a corresponding low level of PKA activity at AQP2-bearing vesicles in resting cells. Nevertheless, basal PKA activity seems to be sufficient to maintain at least a fraction of PDE4D in the PKA-phosphorylated activated state (37, 38) . Therefore, we suggest that a key role for vesicular PDE4D3/9 is to prevent inappropriate translocation of AQP2 to the plasma membrane as a result of small changes in intracellular cAMP levels in resting cells by ensuring the maintenance of low PKA activity. However, a fraction of AQP2 is phosphorylated under resting conditions (39) . It is feasible that basal PKA activity leads to phosphorylation of one or two AQP2 molecules per tetramer. The high cAMP rise that is induced by AVP presumably overcomes the constraining activity of PDE4D3/9, allowing for phosphorylation of at least three AQP2 molecules within an AQP2 tetramer that is needed for the AVP-induced redistribution to occur (42) .
The PKA inhibitor H89 induces retrieval of AQP2 by reducing its phosphorylation and preventing PKA-dependent phosphorylation of other proteins (39) . The presence of activated p-PDE4 at the plasma membrane, subsequent to cAMP elevation (Figure 4) , suggests a role for p-PDE4D3/9 in the termination of the cAMP- Figure 7 . Model for the involvement of PDE4D in the cAMP-triggered redistribution of AQP2. AQP2-bearing vesicles contain AKAP18␦, which directly interacts with PDE4D3/9 and PKA (RII, regulatory RII, and C, catalytic PKA subunits; purple, inactive; red, active PKA). (A) Under resting conditions, PDE4D3/9 maintains vesicular AKAP-tethered PKA activity on a basal level by hydrolysis of local cAMP. A fraction of PDE4D3/9 is activated by PKA phosphorylation in resting cells. (B) Hormonal (AVP) stimulation of principal cells activates adenylyl cyclase, causing a rise in cAMP. cAMP activates PKA, which phosphorylates AQP2 (homotetramer), thereby inducing the exocytic insertion of AQP2 into the plasma membrane. The redistribution requires the phosphorylation of at least three AQP2 monomers in a tetramer. PKA-phosphorylated PDE4D3/9 accumulates together with AQP2 at the plasma membrane, where it is involved in terminating cAMP-dependent water reabsorption. (C) The combination of hormonal treatment and selective PDE4 inhibition (with rolipram) increases the accumulation of AQP2 in the plasma membrane. Elevation of cAMP induces the dissociation of RII subunits from AKAP18␦ (for further explanation, see Discussion and reference [17] ). dependent water reabsorption. Therefore, p-PDE4D3/9 activity may act functionally as H89: Reducing PKA activity in the vicinity of the plasma membrane, thereby terminating endogenous PKA signaling and membrane localization of AQP2.
AQP2 phosphorylation seems necessary but not sufficient for AQP2 plasma membrane expression, suggesting that mechanisms that are independent of AQP2 phosphorylation are involved in the enhancing effect of rolipram on the AVP-induced AQP2 shuttle (22, 43, 44) . One such mechanism may be the PKA-dependent phosphorylation and consequent inhibition of the small GTPase RhoA because AVP-induced RhoA inactivation, through PKA (45) , is a prerequisite for the AQP2 shuttle (22, 23) .
We show here for the first time that vesicle-located AKAP18␦ can interact directly with PDE4D3. Peptide array analyses indicate that AKAP18␦ interacts with two surface-exposed sites on the conserved PDE4D catalytic unit (16, 46) , suggesting that all PDE4D isoforms potentially could interact with AKAP18␦. Therefore AKAP18␦ may act to tether both PDE4D3 and PDE4D9 to AQP2-bearing vesicles. Lack of AKAP18␦ 3D models makes predictions about the identified binding sites unfeasible. That AKAP18␦ binds PDE4D directly, and PKA identifies it as signaling scaffold. This regulatory module may form the basis for cAMP-dependent signaling that is associated with AQP2-bearing vesicles.
The signaling system on AQP2-bearing vesicles may be a suitable target for the treatment of diseases that are associated with disturbances of body water homeostasis. For example, states of water retention that are caused by heart insufficiency or hypertension may be treatable by disruption of AKAP-PKA interaction. This prevents the AQP2 shuttle and further water reabsorption (2) . Interference with PDE4 function increases the AVP-induced rise in cAMP and promotes the AQP2 shuttle, suggesting that PDE4 inhibitors combined with a cAMP-elevating agent may be suitable for treatment of X-linked nephrogenic diabetes insipidus, when the V2R is nonfunctional.
